EyePoint Pharmaceuticals, Inc. Common Stock (EYPT) Stock
NASDAQ · EYPT
3.30
Fundamentals
Market cap
$312.09M
Price / Earnings ratio
-1.0x
Price / Sales ratio
112.8x
Price / Book ratio
1.9x
Return on assets
-90.0%
Ex-Dividend date
N/A
Last payment date
N/A
Dividend amount
$0.00
Dividend yield
0.00%
Debt / Equity ratio
N/A
Recent news

Business Wire
EYPT SHAREHOLDER ALERT: EyePoint Pharmaceuticals Investors Encouraged to Contact Kirby McInerney LLP About Potential Securities Laws Violations
NeutralEYPTSeptember 2, 2026
Business WireNeutral
EYPT SHAREHOLDER ALERT: EyePoint Pharmaceuticals Investors Encouraged to Contact Kirby McInerney LLP About Potential Securities Laws Violations
EYPT

Business Wire
EYPT Investors Have Opportunity to Join EyePoint, Inc. Fraud Investigation with SBS Law
NeutralEYPTAugust 28, 2026
Business WireNeutral
EYPT Investors Have Opportunity to Join EyePoint, Inc. Fraud Investigation with SBS Law
EYPT

Business Wire
NASDAQ: EYPT Investigation Alert: Kessler Topaz Meltzer & Check, LLP Encourages EyePoint, Inc. (NASDAQ: EYPT) Investors to Contact the Firm
NeutralEYPTAugust 26, 2026
Business WireNeutral
NASDAQ: EYPT Investigation Alert: Kessler Topaz Meltzer & Check, LLP Encourages EyePoint, Inc. (NASDAQ: EYPT) Investors to Contact the Firm
EYPT

Business Wire
EYPT Investor Alert: Levi & Korsinsky Notifies Investors of Investigation Into EyePoint Pharmaceuticals (EYPT)
NeutralEYPTAugust 21, 2026
Business WireNeutral
EYPT Investor Alert: Levi & Korsinsky Notifies Investors of Investigation Into EyePoint Pharmaceuticals (EYPT)
EYPT
Technicals
OscillatorsBuy5 Indicators
Moving AveragesStrong Sell12 Indicators
Analyst Ratings
Strong Sell0
Sell0
Neutral5
Buy4
Strong Buy0
Financials
Performance
Revenue
Net income
Net margin %
2025
38M25M12M0
Debt & Balance Sheet
Total assets
Total liabilities
2025
437M288M144M0
Revenue to Profit
2025$31.4M
Revenue$0.0
Cost of revenue$0.0
Gross profit$0.0
Operating expenses$-232.0M
Net incomeEarnings
No data available
% positive news of 10 articles
published over the past 14 days
Latest news

Business Wire
EYPT SHAREHOLDER ALERT: EyePoint Pharmaceuticals Investors Encouraged to Contact Kirby McInerney LLP About Potential Securities Laws Violations
NeutralEYPTSeptember 2, 2026
Business WireNeutral
EYPT SHAREHOLDER ALERT: EyePoint Pharmaceuticals Investors Encouraged to Contact Kirby McInerney LLP About Potential Securities Laws Violations
EYPT

Business Wire
EYPT Investors Have Opportunity to Join EyePoint, Inc. Fraud Investigation with SBS Law
NeutralEYPTAugust 28, 2026
Business WireNeutral
EYPT Investors Have Opportunity to Join EyePoint, Inc. Fraud Investigation with SBS Law
EYPT

Business Wire
NASDAQ: EYPT Investigation Alert: Kessler Topaz Meltzer & Check, LLP Encourages EyePoint, Inc. (NASDAQ: EYPT) Investors to Contact the Firm
NeutralEYPTAugust 26, 2026
Business WireNeutral
NASDAQ: EYPT Investigation Alert: Kessler Topaz Meltzer & Check, LLP Encourages EyePoint, Inc. (NASDAQ: EYPT) Investors to Contact the Firm
EYPT

Business Wire
EYPT Investor Alert: Levi & Korsinsky Notifies Investors of Investigation Into EyePoint Pharmaceuticals (EYPT)
NeutralEYPTAugust 21, 2026
Business WireNeutral
EYPT Investor Alert: Levi & Korsinsky Notifies Investors of Investigation Into EyePoint Pharmaceuticals (EYPT)
EYPT

Zacks Investment Research
EYPT Stock Plunges 67% After Duravyu Misses Phase III Eye Disease Goal
NeutralEYPTAugust 18, 2026
Zacks Investment ResearchNeutral
EYPT Stock Plunges 67% After Duravyu Misses Phase III Eye Disease Goal
EYPT

Stocktwits
Why Did EYPT, STLA, ENVX Stocks Plunge To 52-Week Lows Today?
NeutralEYPTAugust 18, 2026
StocktwitsNeutral
Why Did EYPT, STLA, ENVX Stocks Plunge To 52-Week Lows Today?
EYPT

Stocktwits
OCUL, FDMT Stock Clock Best Day In Weeks After EyePoint’s Trial Setback — Here’s Why
NeutralEYPTAugust 17, 2026
StocktwitsNeutral
OCUL, FDMT Stock Clock Best Day In Weeks After EyePoint’s Trial Setback — Here’s Why
EYPT

Investors Business Daily
The Surprising Reason EyePoint Just Crashed 69%
NeutralEYPTAugust 17, 2026
Investors Business DailyNeutral
The Surprising Reason EyePoint Just Crashed 69%
EYPT

Reuters
EyePoint's eye drug misses main goal in late-stage trial
NeutralEYPTAugust 17, 2026
ReutersNeutral
EyePoint's eye drug misses main goal in late-stage trial
EYPT

Zacks Investment Research
EyePoint (EYPT) Reports Q2 Loss, Beats Revenue Estimates
NeutralEYPTAugust 5, 2026
Zacks Investment ResearchNeutral
EyePoint (EYPT) Reports Q2 Loss, Beats Revenue Estimates
EYPT
About EyePoint Pharmaceuticals, Inc. Common Stock
No description available.
SectorHealthcare
IndustryBiotechnology
Employees214
CEODr. Jay S. Duker M.D.
IPO DateJan 27, 2005
HeadquartersWatertown, MA
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Dr. Jay S. Duker M.D. | President, CEO & Director | 1959 |
| Mr. George O. Elston CPA | Executive VP & CFO | 1965 |
| Dr. Ramiro Ribeiro M.D., Ph.D. | Chief Medical Officer | 1983 |
| Dr. Marcia Sellos-Moura Ph.D. | Chief Scientific Officer | — |
| Mr. Ron I. Honig Esq. | Chief Legal Officer & Company Secretary | — |
| Ms. Jennifer Leonard | Chief People Officer & Senior VP of IT | — |
| Mr. David Scott Jones M.A. | Senior Vice President | 1968 |
| Ms. Isabelle Lefebvre | Chief Regulatory Officer | — |
| Mr. Michael J. Maciocio | Chief Manufacturing Officer | — |
| Mr. Michael Campbell | Chief Commercial Officer | — |
Fundamentals
Valuation
Market cap$312.09M
Price-to-sales ratio112.84
Price-to-book value1.89
Price-earnings ratio-1.00
Return on Equity-111.00%
Return on Sales-3563.00%
Return on Assets-90.00%
PEG ratioN/A
Earnings Per Share
Earnings Per Share$-3.75
Income Statement
Average volume3,835,653
EBITDA$-268.89M
1 year high (52w)$19.11
1 year low (52w)$3.42
Dividend
Ex dividend dateN/A
Dividend amount$0.00
Dividend yield0.00%
Last payment dateN/A
Dividend yield (TTM)N/A
Next earnings reportN/A
Solvency
Debt-to-equity ratioN/A
Technicals
OscillatorsBuy5 Indicators
Moving AveragesStrong Sell12 Indicators
What the experts say
9 Wall Street Analyst Ratings
HOLD
44% Buy
56% Hold
0% Sell
Target price
$19.14
Est return
428.81%
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2021 | +1.4 | +2.3 | +30.1 | -21.1 | ||||||||
| 2022 | -23.7 | +0.7 | +24.0 | -7.0 | -19.7 | -12.2 | +17.8 | +9.8 | -19.9 | -24.3 | -41.0 | +9.4 |
| 2023 | +27.7 | -29.7 | -7.3 | +99.4 | -8.9 | +46.0 | +54.3 | -22.0 | -24.0 | -22.8 | -13.7 | +249.6 |
| 2024 | +19.6 | -4.6 | -26.2 | -13.2 | -40.6 | -11.9 | +18.9 | -2.0 | -2.1 | +47.0 | -26.6 | -15.0 |
| 2025 | -4.7 | -12.6 | -5.2 | +35.0 | +1.5 | +26.8 | +2.8 | +19.2 | +21.4 | +1.3 | +19.1 | +28.1 |
| 2026 | -22.7 | +32.1 | -29.7 | +1.4 | +1.8 | +8.7 | -7.2 | -63.8 | -21.0 |



